ClinicalTrials.gg
CompletedNCT00299130SERENEUpdated Apr 17, 2017Results posted

A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis

A Phase 3 interventional study of Folate and Methotrexate in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-04-17.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
511
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
14th of 113
511 · median 130
Started
2005
with 5 others
Phase 3
47 of 113
1 open now
Registered
13th of 113
by date
Lead sponsor
4 of 113
Genentech, Inc.

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 14th largest by enrollment, is one of 6 that started in 2005, is one of 47 in phase 3, and was the 13th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study evaluated the efficacy and safety of rituximab in patients with active rheumatoid arthritis (RA).

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • RA
  • Rituxan
  • SERENE
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients 18-80 years of age.
  • Rheumatoid arthritis (RA) for ≥ 6 months, diagnosed according to the revised 1987 American College of Rheumatology (ACR) criteria for the classification of rheumatoid arthritis.
  • Receiving outpatient treatment for RA.
  • Swollen joint count (SJC) ≥ 8 (66 joint count), and tender joint count (TJC) ≥ 8 (68 joint count) at screening and baseline.
  • At screening, either

    • C-reactive protein (CRP) ≥ 0.6 mg/dL (6 mg/L), or
    • Erythrocyte sedimentation rate (ESR) ≥ 28 mm/hour.
  • Inadequate response to methotrexate, having received and tolerated at a dose of 10-25 mg/week it for ≥ 12 weeks.

Exclusion criteria

Exclusion criteria:

  • Rheumatic disease other than RA, or significant systemic involvement secondary to RA.
  • Inflammatory joint disease other than RA, or other systemic autoimmune disorder.
  • Diagnosis of juvenile rheumatoid arthritis, or RA before the age of 16.
  • Surgery within 12 weeks of study or planned within 24 weeks of randomization.
  • Previous treatment with any approved or biological agent for RA, an anti-alpha4-integrin antibody or co-stimulation modulator, or cell-depleting therapy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
511 participants (actual)

Study arms

  • Active comparator
    Placebo + methotrexate (MTX)

    Participants received placebo intravenous infusion on Days 1 and 15. From Week 16 onwards, participants could switch to receive rituximab 0.5 g (on Days 1 and 15) every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Placebo and rituximab infusions were preceded with 100 milligrams (mg) intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of MTX and ≥ 5 mg/week folic acid for the duration of their participation in the study. All participants entered a 48-week safety follow-up (SFU) period following the treatment period.

    Drug: Folate · Drug: Methotrexate · Drug: Methylprednisolone · Drug: Placebo · Drug: Rituximab

  • Experimental
    Rituximab 2 x 0.5 g + MTX

    Participants received 0.5 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study. All participants entered a 48-week safety follow-up (SFU) period following the treatment period.

    Drug: Folate · Drug: Methotrexate · Drug: Methylprednisolone · Drug: Rituximab

  • Experimental
    Rituximab 2 x 1.0 g + MTX

    Participants received 1.0 g rituximab administered by intravenous infusion on Days 1 and 15. After Week 24, participants received further courses of rituximab every 24 weeks for up to 5 years if they were not in clinical remission and safety criteria were met. Rituximab infusions were preceded with 100 mg intravenous methylprednisolone. Participants also received a stable dose of 10-25 mg/week of methotrexate and ≥ 5 mg/week folic acid for the duration of their participation in the study. All participants entered a 48-week safety follow-up (SFU) period following the treatment period.

    Drug: Folate · Drug: Methotrexate · Drug: Methylprednisolone · Drug: Rituximab

Interventions

  • DrugFolate

    A stable dose, ≥ 5 mg/week given as either a single dose or as a divided weekly dose, orally.

  • A stable dose of between 10-25 mg/week, oral or parenteral, as prescribed by the treating physician.

  • Intravenous infusion

  • DrugPlacebo

    Placebo to rituximab intravenous infusion

  • Intravenous infusion

    Also known as: MabThera®, Rituxan®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24

    To achieve an ACR20 required at least a 20% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 20% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to Week 24, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Percentage of Participants With an ACR50 Response at Week 24

    To achieve an ACR50 required at least a 50% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 50% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to Week 24, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.

    Time frame: Baseline and Week 24

  2. Percentage of Participants With an ACR70 Response at Week 24

    To achieve an ACR70 required at least a 70% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 70% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to Week 24, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.

    Time frame: Baseline and Week 24

  3. Change From Baseline in Disease Activity Score (DAS28-ESR) at Week 24

    The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables: * The number of swollen and tender joints assessed using the 28-joint count; * Erythrocyte sedimentation rate (ESR); * Patient's global assessment of disease activity measured on a 100 mm visual analog scale. The DAS28 score ranges from zero to ten. A DAS28 score above 5.1 means high disease activity whereas a DAS28 less than or equal to 3.2 indicates low disease activity. Remission is achieved by a DAS28 lower than 2.6.

    Time frame: Baseline and Week 24

  4. Percentage of Participants With European League Against Rheumatism (EULAR) Response at Week 24

    A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS28 score. The DAS28 score ranges from 0-10, with higher scores indicating more disease activity. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score of less than or equal to 3.2. A Moderate Response is defined as either: * an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 from Baseline and attainment of a DAS28 score of less than or equal to 5.1 or, * an improvement (decrease) in the DAS28 of more than 1.2 from Baseline and attainment of a DAS28 score of greater than 3.2. No Response is defined as either an improvement (decrease) in the DAS28 of less than or equal to 0.6, or an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 of more than 5.1.

    Time frame: Baseline and Week 24

  5. Percent Change From Baseline in Swollen Joint Count

    Sixty-six joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.

    Time frame: Baseline, Week 24 and Week 48

  6. Percent Change From Baseline in Tender Joint Count

    Sixty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.

    Time frame: Baseline, Week 24 and Week 48

  7. Percent Change From Baseline in Patient's Global Assessment of Disease Activity

    The participant's overall assessment of their current disease activity measured on a 100 mm horizontal visual analog scale (VAS). The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme (100 mm) as "maximum disease activity" (maximum arthritis disease activity). The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.

    Time frame: Baseline, Week 24 and Week 48

  8. Percent Change From Baseline in Patient's Pain Assessment

    The participant's assessment of their current level of pain on a 100 mm horizontal visual analog scale (VAS), where the left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand extreme (100 mm) as "unbearable pain". The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.

    Time frame: Baseline, Week 24 and Week 48

  9. Percent Change From Baseline in Physician's Global Assessment of Disease Activity

    The physician's assessment of the participant's current disease activity on a 100 mm horizontal VAS, where the left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme (100 mm) as "maximum disease activity". The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.

    Time frame: Baseline, Week 24 and Week 48

  10. Percent Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score

    The Stanford Health Assessment Questionnaire disability index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants choose from four response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.

    Time frame: Baseline, Week 24 and Week 48

  11. Percent Change From Baseline in C-Reactive Protein

    C-Reactive Protein (CRP) was measured from blood samples by a central laboratory as a marker for inflammation. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.

    Time frame: Baseline, Week 24 and Week 48

  12. Percent Change From Baseline in Erythrocyte Sedimentation Rate

    Erythrocyte sedimentation rate (ESR) indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.

    Time frame: Baseline, Week 24 and Week 48

  13. Percent Change From Baseline in Short Form 36 Health Survey (SF-36) Summary Scores (Physical and Mental Components)

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions split into two major components: physical health and mental health. Under physical health are the following four domains: physical health, bodily pain, physical functioning and physical role limitations. Under the mental health domain there are four domains; mental health, vitality, social functioning, and emotional role limitation. The individual domain scores are aggregated to derive a physical-component summary score and a mental-component summary score which range from 0 to 100, with higher scores indicating a better level of functioning. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A positive percentage change from baseline score indicates an improvement.

    Time frame: Baseline, Week 24 and Week 48

  14. Change From Baseline in Short Form 36 Health Survey (SF-36) General Health Domain Score

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.

    Time frame: Baseline, Week 24 and Week 48

  15. Change From Baseline in Short Form 36 Health Survey (SF-36) Bodily Pain Domain Score

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.

    Time frame: Baseline, Week 24 and Week 48

  16. Change From Baseline in Short Form 36 Health Survey (SF-36) Physical Functioning Domain Score

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.

    Time frame: Baseline, Week 24 and Week 48

  17. Change From Baseline in Short Form 36 Health Survey (SF-36) Physical Role Limitations Domain Score

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.

    Time frame: Baseline, Week 24 and Week 48

  18. Change From Baseline in Short Form 36 Health Survey (SF-36) Mental Health Domain Score

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.

    Time frame: Baseline, Week 24 and Week 48

  19. Change From Baseline in Short Form 36 Health Survey (SF-36) Vitality Domain Score

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.

    Time frame: Baseline, Week 24 and Week 48

  20. Change From Baseline in Short Form 36 Health Survey (SF-36) Social Functioning Domain Score

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.

    Time frame: Baseline, Week 24 and Week 48

  21. Change From Baseline in Short Form 36 Health Survey (SF-36) Emotional Role Limitations Domain Score

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.

    Time frame: Baseline, Week 24 and Week 48

  22. Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Scores

    The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days. Participants respond to the questions using a value in the range of 0 (not at all) to 4 (very much). The scale score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from baseline score indicates an improvement.

    Time frame: Baseline, Week 24 and Week 48

  23. Percentage of Participants With DAS28-ESR Low Disease Activity Score and Clinical Remission at Week 24

    The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables: * The number of swollen and tender joints assessed using the 28-joint count; * Erythrocyte sedimentation rate (ESR); * Patient's global assessment of disease activity measured on a 100 mm visual analog scale. The DAS28 score ranges from zero to ten. DAS28 above 5.1 indicates high disease activity. Low disease activity is defined by a DAS28 score less than or equal to 3.2. Remission is defined by a DAS28 score less than 2.6.

    Time frame: Week 24

  24. Percentage of Participants With HAQ-DI Improved, Unchanged or Worsened at Week 24

    The Stanford Health Assessment Questionnaire disability index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants choose from four response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A negative change from baseline score indicates an improvement. Improved HAQ-DI is defined as a change from Baseline score less than or equal to -0.22. An Unchanged HAQ-DI is defined as a change from Baseline score greater than -0.22 and less than 0.22. A worsened HAQ-DI score is defined as a change from Baseline score of greater than or equal to 0.22.

    Time frame: Baseline and Week 24

  25. Percentage of Participants With HAQ-DI Improved, Unchanged or Worsened at Week 48

    The Stanford Health Assessment Questionnaire disability index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants choose from four response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A negative change from baseline score indicates an improvement. Improved HAQ-DI is defined as a change from Baseline score less than or equal to -0.22. An Unchanged HAQ-DI is defined as a change from Baseline score greater than -0.22 and less than 0.22. A worsened HAQ-DI score is defined as a change from Baseline score of greater than or equal to 0.22.

    Time frame: Baseline and Week 48

  26. Percentage of Participants With European League Against Rheumatism (EULAR) Response at Week 48

    A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: * an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, * an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2. No Response is defined as either an improvement (decrease) in the DAS28 of less than or equal to 0.6, or an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of 5.1 or higher.

    Time frame: Baseline and Week 48

  27. Percentage of Participants With DAS28-ESR Low Disease Activity Score and Clinical Remission at Week 48

    The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables: * The number of swollen and tender joints assessed using the 28-joint count; * Erythrocyte sedimentation rate (ESR); * Patient's global assessment of disease activity measured on a 100 mm visual analog scale. The DAS28 score ranges from zero to ten. DAS28 above 5.1 indicates high disease activity. Low disease activity is defined by a DAS28 score less than or equal to 3.2. Remission is defined by a DAS28 score less than 2.6.

    Time frame: Week 48

  28. Percentage of Participants With an ACR50 Response at Week 48

    To achieve an ACR50 required at least a 50% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 50% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to week 48, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.

    Time frame: Baseline and Week 48

  29. Percentage of Participants With an ACR70 Response at Week 48

    To achieve an ACR70 required at least a 70% improvement compared with baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 70% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to Week 48, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.

    Time frame: Baseline and Week 48

07

Results

Posted Jun 28, 2013

Participant flow

A total of 511 participants were recruited and randomized between 27 Oct 2005 and 15 Nov 2006. Of these, 2 participants were randomized but received no infusions (one violated inclusion criteria and the other was randomized to rituximab 2 x 1.0 gram \[g\] + methotrexate \[MTX\] but failed to return). A total of 509 participants were treated.

Treatment Period (up to 5 Years)
Participant flow — Treatment Period (up to 5 Years)
MilestonePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Started172168171
Treated172167170
Completed 24 weeks159162166
Completed 48 weeks155157158
Completed 144 weeks133138132
Completed119125121
Not completed534350
Withdrew: Adverse event13813
Withdrew: Death131
Withdrew: Insufficient therapeutic response1966
Withdrew: Protocol violation010
Withdrew: Refused treatment121219
Withdrew: Failure to return466
Withdrew: Reason not specified464
Withdrew: Withdrawal by subject011
Safety Follow-up (SFU) (48 Weeks)
Participant flow — Safety Follow-up (SFU) (48 Weeks)
MilestonePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Started167165168
Completed122120123
Not completed454545
Withdrew: Administrative/other494
Withdrew: Death453
Withdrew: Did not co-operate112
Withdrew: Failure to return14715
Withdrew: No sfu week 48 date recorded010
Withdrew: Withdrawal by subject222221
Extended SFU (ESFU) (up to 5.1 Years)
Participant flow — Extended SFU (ESFU) (up to 5.1 Years)
MilestonePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Started08244
Completed07438
Not completed086
Withdrew: Death030
Withdrew: Failure to return022
Withdrew: Did not cooperate/withdrew consent034

Outcome measures

PrimaryPercentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24

To achieve an ACR20 required at least a 20% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 20% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to Week 24, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24
percentage of participantsPlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 2423.354.550.6
SecondaryPercentage of Participants With an ACR50 Response at Week 24

To achieve an ACR50 required at least a 50% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 50% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to Week 24, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR50 Response at Week 24
percentage of participantsPlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Percentage of Participants With an ACR50 Response at Week 249.326.325.9
SecondaryPercentage of Participants With an ACR70 Response at Week 24

To achieve an ACR70 required at least a 70% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 70% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to Week 24, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR70 Response at Week 24
percentage of participantsPlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Percentage of Participants With an ACR70 Response at Week 245.29.010.0
SecondaryChange From Baseline in Disease Activity Score (DAS28-ESR) at Week 24

The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables: * The number of swollen and tender joints assessed using the 28-joint count; * Erythrocyte sedimentation rate (ESR); * Patient's global assessment of disease activity measured on a 100 mm visual analog scale. The DAS28 score ranges from zero to ten. A DAS28 score above 5.1 means high disease activity whereas a DAS28 less than or equal to 3.2 indicates low disease activity. Remission is achieved by a DAS28 lower than 2.6.

Time frame:
Baseline and Week 24
Reported as:
Mean · scores on a scale
Change From Baseline in Disease Activity Score (DAS28-ESR) at Week 24
scores on a scalePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Change From Baseline in Disease Activity Score (DAS28-ESR) at Week 24-0.76 ± 1.304-1.71 ± 1.334-1.68 ± 1.342
SecondaryPercentage of Participants With European League Against Rheumatism (EULAR) Response at Week 24

A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS28 score. The DAS28 score ranges from 0-10, with higher scores indicating more disease activity. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score of less than or equal to 3.2. A Moderate Response is defined as either: * an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 from Baseline and attainment of a DAS28 score of less than or equal to 5.1 or, * an improvement (decrease) in the DAS28 of more than 1.2 from Baseline and attainment of a DAS28 score of greater than 3.2. No Response is defined as either an improvement (decrease) in the DAS28 of less than or equal to 0.6, or an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 of more than 5.1.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With European League Against Rheumatism (EULAR) Response at Week 24
percentage of participantsPlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
No Response66.333.537.1
Moderate Response29.149.151.2
Good Response4.717.411.8
SecondaryPercent Change From Baseline in Swollen Joint Count

Sixty-six joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Swollen Joint Count
percent changePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Week 24 [N=172, 166, 170]-21.6 ± 65.82-47.4 ± 43.49-49.1 ± 38.59
Week 48 [N=172, 166, 170]-38.9 ± 66.83-54.0 ± 38.66-59.3 ± 37.04
SecondaryPercent Change From Baseline in Tender Joint Count

Sixty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Tender Joint Count
percent changePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Week 24 [N=172, 166, 170]-14.2 ± 69.20-42.5 ± 64.41-31.5 ± 66.52
Week 48 [N=172, 166, 170]-37.1 ± 55.08-50.2 ± 62.74-45.1 ± 62.64
SecondaryPercent Change From Baseline in Patient's Global Assessment of Disease Activity

The participant's overall assessment of their current disease activity measured on a 100 mm horizontal visual analog scale (VAS). The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme (100 mm) as "maximum disease activity" (maximum arthritis disease activity). The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Patient's Global Assessment of Disease Activity
percent changePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Week 24 [N=171, 166, 169]-14.0 ± 48.94-31.5 ± 46.40-29.1 ± 54.43
Week 48 [N=171, 166, 169]-28.0 ± 50.78-39.7 ± 40.53-36.6 ± 47.60
SecondaryPercent Change From Baseline in Patient's Pain Assessment

The participant's assessment of their current level of pain on a 100 mm horizontal visual analog scale (VAS), where the left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand extreme (100 mm) as "unbearable pain". The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Patient's Pain Assessment
percent changePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Week 24 [N=171, 166, 169]-9.7 ± 52.58-25.7 ± 58.52-29.1 ± 53.11
Week 48 [N=171, 166, 169]-24.4 ± 60.22-35.5 ± 50.45-36.3 ± 47.87
SecondaryPercent Change From Baseline in Physician's Global Assessment of Disease Activity

The physician's assessment of the participant's current disease activity on a 100 mm horizontal VAS, where the left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme (100 mm) as "maximum disease activity". The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Physician's Global Assessment of Disease Activity
percent changePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Week 24 [N=172, 166, 170]-25.3 ± 38.52-36.9 ± 61.26-35.4 ± 46.99
Week 48 [N=172, 166, 170]-39.4 ± 39.95-40.5 ± 74.54-49.0 ± 40.01
SecondaryPercent Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score

The Stanford Health Assessment Questionnaire disability index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants choose from four response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score
percent changePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Week 24 [N=172, 165, 170]-14.7 ± 38.41-26.9 ± 40.89-23.4 ± 49.52
Week 48 [N=172, 165, 170]-22.6 ± 39.63-30.2 ± 41.64-30.6 ± 39.95
SecondaryPercent Change From Baseline in C-Reactive Protein

C-Reactive Protein (CRP) was measured from blood samples by a central laboratory as a marker for inflammation. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in C-Reactive Protein
percent changePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Week 24 [N=172, 166, 170]58.1 ± 385.23-27.5 ± 84.36-23.1 ± 119.75
Week 48 [N=172, 166, 170]40.1 ± 402.67-37.3 ± 94.65-34.9 ± 82.40
SecondaryPercent Change From Baseline in Erythrocyte Sedimentation Rate

Erythrocyte sedimentation rate (ESR) indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A negative percentage change from baseline score indicates an improvement.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Erythrocyte Sedimentation Rate
percent changePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Week 24 [N=172, 166, 169]8.0 ± 130.71-28.0 ± 42.20-29.2 ± 52.32
Week 48 [N=172, 166, 169]-14.5 ± 68.55-31.3 ± 49.72-36.7 ± 51.49
SecondaryPercent Change From Baseline in Short Form 36 Health Survey (SF-36) Summary Scores (Physical and Mental Components)

The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions split into two major components: physical health and mental health. Under physical health are the following four domains: physical health, bodily pain, physical functioning and physical role limitations. Under the mental health domain there are four domains; mental health, vitality, social functioning, and emotional role limitation. The individual domain scores are aggregated to derive a physical-component summary score and a mental-component summary score which range from 0 to 100, with higher scores indicating a better level of functioning. The percentage change from baseline at each post-baseline visit was calculated as: \[(post-baseline value minus baseline value) divided by Baseline value\]\*100. A positive percentage change from baseline score indicates an improvement.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Short Form 36 Health Survey (SF-36) Summary Scores (Physical and Mental Components)
percent changePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Physical Component: Week 24 [N=147, 152, 155]11.1 ± 27.6323.7 ± 31.6322.8 ± 33.09
Physical Component: Week 48 [N=154, 154, 162]21.3 ± 30.9926.4 ± 35.8127.4 ± 31.93
Mental Component: Week 24 [N=147, 152, 155]8.4 ± 29.4312.6 ± 29.1319.6 ± 56.64
Mental Component: Week 48 [N=154, 154, 162]12.7 ± 30.5218.4 ± 38.8718.7 ± 57.34
SecondaryChange From Baseline in Short Form 36 Health Survey (SF-36) General Health Domain Score

The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · scores on a scale
Change From Baseline in Short Form 36 Health Survey (SF-36) General Health Domain Score
scores on a scalePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Week 24 [N=138, 154, 155]2.078 ± 7.30323.532 ± 8.27473.866 ± 9.2154
Week 48 [N=137, 148, 147]4.214 ± 8.23524.165 ± 9.58944.362 ± 8.1242
SecondaryChange From Baseline in Short Form 36 Health Survey (SF-36) Bodily Pain Domain Score

The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · scores on a scale
Change From Baseline in Short Form 36 Health Survey (SF-36) Bodily Pain Domain Score
scores on a scalePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Week 24 [N=138, 152, 156]3.304 ± 8.56316.931 ± 8.22547.604 ± 8.5238
Week 48 [N=137, 147, 147]8.449 ± 9.35438.079 ± 9.54358.964 ± 8.9890
SecondaryChange From Baseline in Short Form 36 Health Survey (SF-36) Physical Functioning Domain Score

The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · scores on a scale
Change From Baseline in Short Form 36 Health Survey (SF-36) Physical Functioning Domain Score
scores on a scalePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Week 24 [N=138, 154, 154]3.553 ± 8.41815.460 ± 8.30995.653 ± 9.6817
Week 48 [N=137, 148, 146]6.212 ± 9.68826.778 ± 8.71176.854 ± 9.3833
SecondaryChange From Baseline in Short Form 36 Health Survey (SF-36) Physical Role Limitations Domain Score

The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · scores on a scale
Change From Baseline in Short Form 36 Health Survey (SF-36) Physical Role Limitations Domain Score
scores on a scalePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Week 24 [N=136, 153, 156]2.713 ± 8.72635.618 ± 9.04595.175 ± 8.8018
Week 48 [N=137, 148, 147]6.423 ± 9.67526.812 ± 9.86336.497 ± 8.4820
SecondaryChange From Baseline in Short Form 36 Health Survey (SF-36) Mental Health Domain Score

The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · scores on a scale
Change From Baseline in Short Form 36 Health Survey (SF-36) Mental Health Domain Score
scores on a scalePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Week 24 [N=137, 153, 156]3.278 ± 8.68502.770 ± 9.99434.486 ± 9.4930
Week 48 [N=135, 147, 147]3.890 ± 8.74934.583 ± 10.56254.224 ± 9.9831
SecondaryChange From Baseline in Short Form 36 Health Survey (SF-36) Vitality Domain Score

The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · scores on a scale
Change From Baseline in Short Form 36 Health Survey (SF-36) Vitality Domain Score
scores on a scalePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Week 24 [N=137, 154, 156]3.631 ± 8.76624.230 ± 9.36315.910 ± 9.5802
Week 48 [N=135, 147, 147]6.853 ± 9.82215.925 ± 10.14955.869 ± 9.6168
SecondaryChange From Baseline in Short Form 36 Health Survey (SF-36) Social Functioning Domain Score

The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · scores on a scale
Change From Baseline in Short Form 36 Health Survey (SF-36) Social Functioning Domain Score
scores on a scalePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Week 24 [N=138, 154, 156]2.529 ± 9.64355.985 ± 10.29866.468 ± 10.8868
Week 48 [N=137, 148, 147]6.569 ± 10.66747.112 ± 11.53296.159 ± 11.0244
SecondaryChange From Baseline in Short Form 36 Health Survey (SF-36) Emotional Role Limitations Domain Score

The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. A positive change from baseline score indicates an improvement.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · scores on a scale
Change From Baseline in Short Form 36 Health Survey (SF-36) Emotional Role Limitations Domain Score
scores on a scalePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Week 24 [N=136, 151, 155]1.829 ± 11.54054.634 ± 11.64194.464 ± 13.6883
Week 48 [N=137, 146, 146]4.724 ± 12.26496.257 ± 12.96404.446 ± 13.4036
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Scores

The FACIT-Fatigue questionnaire is a self-administered patient questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days. Participants respond to the questions using a value in the range of 0 (not at all) to 4 (very much). The scale score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue. A positive change from baseline score indicates an improvement.

Time frame:
Baseline, Week 24 and Week 48
Reported as:
Mean · scores on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Scores
scores on a scalePlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Week 24 [N=170, 165, 168]2.661 ± 9.50935.564 ± 9.74386.398 ± 10.2143
Week 48 [N=170, 165, 169]5.506 ± 10.96516.269 ± 9.74956.203 ± 9.7833
SecondaryPercentage of Participants With DAS28-ESR Low Disease Activity Score and Clinical Remission at Week 24

The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables: * The number of swollen and tender joints assessed using the 28-joint count; * Erythrocyte sedimentation rate (ESR); * Patient's global assessment of disease activity measured on a 100 mm visual analog scale. The DAS28 score ranges from zero to ten. DAS28 above 5.1 indicates high disease activity. Low disease activity is defined by a DAS28 score less than or equal to 3.2. Remission is defined by a DAS28 score less than 2.6.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28-ESR Low Disease Activity Score and Clinical Remission at Week 24
percentage of participantsPlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Low Disease Activity4.717.512.4
Clinical Remission2.39.69.4
SecondaryPercentage of Participants With HAQ-DI Improved, Unchanged or Worsened at Week 24

The Stanford Health Assessment Questionnaire disability index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants choose from four response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A negative change from baseline score indicates an improvement. Improved HAQ-DI is defined as a change from Baseline score less than or equal to -0.22. An Unchanged HAQ-DI is defined as a change from Baseline score greater than -0.22 and less than 0.22. A worsened HAQ-DI score is defined as a change from Baseline score of greater than or equal to 0.22.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With HAQ-DI Improved, Unchanged or Worsened at Week 24
percentage of participantsPlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Improved47.766.158.2
No change32.623.632.4
Worsened19.810.39.4
SecondaryPercentage of Participants With HAQ-DI Improved, Unchanged or Worsened at Week 48

The Stanford Health Assessment Questionnaire disability index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants choose from four response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A negative change from baseline score indicates an improvement. Improved HAQ-DI is defined as a change from Baseline score less than or equal to -0.22. An Unchanged HAQ-DI is defined as a change from Baseline score greater than -0.22 and less than 0.22. A worsened HAQ-DI score is defined as a change from Baseline score of greater than or equal to 0.22.

Time frame:
Baseline and Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HAQ-DI Improved, Unchanged or Worsened at Week 48
percentage of participantsPlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Improved54.773.368.8
No change29.117.025.3
Worsened16.39.75.9
SecondaryPercentage of Participants With European League Against Rheumatism (EULAR) Response at Week 48

A EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 of more than 1.2 compared with Baseline and attainment of a DAS28 score less than or equal to 3.2. A Moderate Response is defined as either: * an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, * an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2. No Response is defined as either an improvement (decrease) in the DAS28 of less than or equal to 0.6, or an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of 5.1 or higher.

Time frame:
Baseline and Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With European League Against Rheumatism (EULAR) Response at Week 48
percentage of participantsPlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
No Response41.326.931.8
Moderate Response41.953.347.6
Good Response16.919.820.6
SecondaryPercentage of Participants With DAS28-ESR Low Disease Activity Score and Clinical Remission at Week 48

The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables: * The number of swollen and tender joints assessed using the 28-joint count; * Erythrocyte sedimentation rate (ESR); * Patient's global assessment of disease activity measured on a 100 mm visual analog scale. The DAS28 score ranges from zero to ten. DAS28 above 5.1 indicates high disease activity. Low disease activity is defined by a DAS28 score less than or equal to 3.2. Remission is defined by a DAS28 score less than 2.6.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28-ESR Low Disease Activity Score and Clinical Remission at Week 48
percentage of participantsPlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Low Disease Activity18.120.024.3
Clinical Remission7.09.111.2
SecondaryPercentage of Participants With an ACR50 Response at Week 48

To achieve an ACR50 required at least a 50% improvement compared with Baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 50% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to week 48, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.

Time frame:
Baseline and Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR50 Response at Week 48
percentage of participantsPlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Percentage of Participants With an ACR50 Response at Week 4818.632.934.1
SecondaryPercentage of Participants With an ACR70 Response at Week 48

To achieve an ACR70 required at least a 70% improvement compared with baseline in both tender joint counts (68 joints assessed for tenderness) and swollen joint counts (66 joints assessed for swelling), as well as a 70% improvement in three of the following five additional measurements: * Physician's global assessment of disease activity (assessed using a 100 mm Visual Analog Scale \[VAS\]); * Patient's global assessment of disease activity (assessed using a 100 mm VAS); * Patient's assessment of pain (assessed using a 100 mm VAS); * Health Assessment Questionnaire (HAQ; a patient completed questionnaire consisting of 20 questions, scored from 0-3); * Acute phase reactant: C-reactive protein (CRP) or, if CRP was missing, erythrocyte sedimentation rate (ESR). Participants who withdrew prematurely from the study prior to Week 48, who received rescue therapy or had insufficient data in order to calculate a clinical response were considered to be non-responders.

Time frame:
Baseline and Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR70 Response at Week 48
percentage of participantsPlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Percentage of Participants With an ACR70 Response at Week 489.312.613.5
Post-hocTime to Repletion of Peripheral CD19+ B-cells

Peripheral CD19+ B-cell repletion was defined as a CD19+ B-cell count that returned to the Baseline value or returned to ≥ the lower limit of normal, whichever was lower.

Time frame:
Beginning of the first infusion (Day 1) in the last treatment cycle until repletion or the end of the study (approximately 6.5 years)
Reported as:
Median · Weeks
Time to Repletion of Peripheral CD19+ B-cells
WeeksRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTX
Time to Repletion of Peripheral CD19+ B-cells110.3 (89.6 to 148.3)109.6 (94.1 to 134.9)
Post-hocPercentage of Participants With Low Immunoglobulin Concentrations Pre- and Post-Rituximab Treatment

A low immunoglobulin concentration was defined as a concentration below the lower level of normal.

Time frame:
Baseline (pre-rituximab), Beginning of the safety follow-up period to the end of the study (approximately 6 years) (post-rituximab)
Reported as:
Number · Percentage of participants
Percentage of Participants With Low Immunoglobulin Concentrations Pre- and Post-Rituximab Treatment
Percentage of participantsRituximab + MTX
Pre-Rituximab (N=490)0.2
Post-Rituximab (N=491)5.1

Adverse events

Collected over Up to 5.1 years after last dose in treatment period (treatment period = up to 5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + MTX—16/172 (9.3%)112/172 (65.1%)
Rituximab 2 x 0.5 g + MTX—52/167 (31.1%)149/167 (89.2%)
Rituximab 1.0 g + MTX—46/170 (27.1%)151/170 (88.8%)
Switch Population: Placebo + MTX—12/155 (7.7%)99/155 (63.9%)
Switch Population: Rituximab—45/155 (29%)131/155 (84.5%)
Rituximab 2 x 0.5 g + MTX - Extended Safety Follow-up Period—8/82 (9.8%)5/82 (6.1%)
Rituximab 2 x 1.0 g + MTX - Extended Safety Follow-up Period—2/44 (4.5%)2/44 (4.5%)
Most frequent serious events
Showing 10 of 153
Most frequent serious events
EventPlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 1.0 g + MTXSwitch Population: Placebo + MTXSwitch Population: RituximabRituximab 2 x 0.5 g + MTX - Extended Safety Follow-up PeriodRituximab 2 x 1.0 g + MTX - Extended Safety Follow-up Period
OsteoarthritisMusculoskeletal and connective tissue disorders1/1724/1675/1701/1550/1550/820/44
FallInjury, poisoning and procedural complications1/1724/1673/1700/1553/1550/820/44
Myocardial infarctionCardiac disorders0/1724/1670/1700/1550/1550/820/44
PneumoniaInfections and infestations1/1723/1674/1701/1553/1551/820/44
Angina pectorisCardiac disorders0/1720/1671/1700/1551/1550/821/44
HypoglycaemiaMetabolism and nutrition disorders0/1720/1670/1700/1550/1550/821/44
Coronary artery diseaseCardiac disorders2/1723/1671/1702/1553/1550/820/44
Cerebrovascular accidentNervous system disorders1/1720/1670/1701/1553/1551/820/44
Urinary tract infectionInfections and infestations0/1723/1671/1700/1551/1550/820/44
CellulitisInfections and infestations0/1723/1671/1700/1550/1550/820/44
Most frequent other events
Showing 10 of 40
Most frequent other events
EventPlacebo + MTXRituximab 2 x 0.5 g + MTXRituximab 1.0 g + MTXSwitch Population: Placebo + MTXSwitch Population: RituximabRituximab 2 x 0.5 g + MTX - Extended Safety Follow-up PeriodRituximab 2 x 1.0 g + MTX - Extended Safety Follow-up Period
Upper respiratory tract infectionInfections and infestations13/17259/16750/17013/15539/1550/820/44
Infusion related reactionInjury, poisoning and procedural complications33/17259/16759/17028/15539/155——
Rheumatoid arthritisMusculoskeletal and connective tissue disorders30/17249/16736/17026/15531/155——
NasopharyngitisInfections and infestations17/17243/16742/17016/15534/1550/820/44
Urinary tract infectionInfections and infestations12/17241/16725/1709/15534/1555/822/44
SinusitisInfections and infestations6/17224/16721/1706/15529/1550/820/44
HypertensionVascular disorders3/17228/16718/1702/15515/155——
BronchitisInfections and infestations3/17227/16725/1702/15524/1550/820/44
DiarrhoeaGastrointestinal disorders7/17227/16720/1707/15520/155——
Back painMusculoskeletal and connective tissue disorders3/17222/16714/1703/15510/155——

Baseline characteristics

Safety population included all randomized participants who received any part of an infusion.

Age, Continuous
Age, Continuous(years)Placebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTXTotal
Mean52.16 ± 12.3951.91 ± 12.9351.30 ± 12.6451.80 ± 12.64
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + MTXRituximab 2 x 0.5 g + MTXRituximab 2 x 1.0 g + MTXTotal
Female147133138418
Male25343291
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, Latinis K, Abud-Mendoza C, Szczepanski LJ, Roschmann RA, Chen A, Armstrong GK, Douglass W, Tyrrell H. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010 Sep;69(9):1629-35. doi: 10.1136/ard.2009.119933. Epub 2010 May 20. Erratum In: Ann Rheum Dis. 2011 Aug;70(8):1519. PubMed 20488885 ↗
  • Lal P, Su Z, Holweg CT, Silverman GJ, Schwartzman S, Kelman A, Read S, Spaniolo G, Monroe JG, Behrens TW, Townsend MJ. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment. Arthritis Rheum. 2011 Dec;63(12):3681-91. doi: 10.1002/art.30596. PubMed 22127691 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Jun 2008 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 5 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2006
First posted
Mar 6, 2006
Start
Oct 2005
Primary completionActual
Jun 2008
CompletionActual
Jul 2013
Results first posted
Jun 28, 2013
Last update
Apr 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00299130
Lead sponsor
Genentech, Inc.
Collaborators
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 6, 2006
Start date
Oct 2005
Primary completion
Jun 2008
Completion
Jul 2013
Results posted
Jun 28, 2013
Last update
Apr 17, 2017

Study contacts

Clinical Trials
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methotrexate · Rituximab

Start the discussion